Real-World Study of Bispecific Antibody in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
A Real-World Study on the Efficacy and Safety of Bispecific Antibody in the Treatment of Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
B-cell non-Hodgkin lymphoma (B-NHL) is the most common type of lymphoma. Although first-line R-CHOP can cure a proportion of patients, approximately 30%-40% relapse or become refractory (R/R). CD20xCD3 bispecific antibodies, represented by glofitamab, have shown significant efficacy in clinical trials. However, large-scale real-world efficacy and safety data in Chinese clinical practice are still lacking, particularly regarding combination with different regimens and use in the relapsed population.
This is a prospective, multicenter, observational registry study evaluating the efficacy and safety of CD20xCD3 bispecific antibody-containing regimens in patients with relapsed or refractory B-cell non-Hodgkin lymphoma in a real-world setting. Efficacy is assessed using the Lugano 2014 response criteria. The primary endpoint is best objective response rate (ORR).
연구 개요
상세 설명
Study design: Prospective, multicenter, observational (non-interventional) registry study.
Population: Patients aged >=18 years with histologically confirmed B-cell non-Hodgkin lymphoma who are relapsed or refractory after at least one prior line of therapy and who receive a CD20xCD3 bispecific antibody-containing regimen after study initiation.
Efficacy evaluation: Lugano 2014 response criteria.
Primary endpoint: Best objective response rate (ORR).
Secondary endpoints: Complete response rate (CRR), disease control rate (DCR), duration of response (DOR), time to next treatment (TTNT), progression-free survival (PFS), overall survival (OS), and safety.
Exploratory endpoints: Subgroup analyses by combination pattern (e.g., combined with chemotherapy or targeted agents) and special populations; correlation of biomarkers (e.g., peripheral blood lymphocyte subsets, T-lymphocyte mitochondrial immune analysis, cytokines) with efficacy and safety; and patient compliance and quality-of-life analyses based on electronic patient-reported outcomes (ePRO).
Planned enrollment: 200 participants. As a non-interventional study, no formal statistical hypothesis is tested; the sample size is based on the confidence-interval width method (expected ORR P=0.5, half-width d=0.07), yielding approximately 196 participants, rounded to 200.
연구 유형
등록 (추정된)
연락처 및 위치
연구 연락처
- 이름: Yanyan Liu
- 전화번호: +86 13838176375
- 이메일: yyliu@zzu.edu.cn
연구 장소
-
-
Henan
-
Zhengzhou, Henan, 중국
- Henan Cancer Hospital
-
연락하다:
- Yanyan Liu
- 전화번호: +86 13838176375
- 이메일: yyliu@zzu.edu.cn
-
-
참여기준
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
샘플링 방법
연구 인구
설명
Inclusion Criteria:
- Age >= 18 years at the start of treatment
- Histologically confirmed B-cell non-Hodgkin lymphoma
- Relapsed or refractory disease after at least one prior line of systemic therapy
- Planned to receive a CD20xCD3 bispecific antibody-containing regimen after study initiation
- Signed informed consent for the investigational treatment
Exclusion Criteria:
- Currently participating in, or planning to participate in, any interventional clinical trial
- Any other condition that, in the investigator's judgment, makes the patient unsuitable for participation in this study
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
코호트 및 개입
그룹/코호트 |
개입 / 치료 |
|---|---|
|
R/R B-NHL treated with bispecific antibody
Patients with relapsed or refractory B-cell non-Hodgkin lymphoma who receive a CD20xCD3 bispecific antibody-containing regimen (e.g., glofitamab) in routine clinical practice.
This is a single observational cohort; no treatment is assigned by the study.
|
Glofitamab, a CD20xCD3 bispecific monoclonal antibody, administered per real-world clinical practice and product labeling.
As an observational study, treatment is determined by the treating physician and not by the study protocol; the intervention of interest is recorded to describe the treated population.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Best Overall Response Rate (ORR)
기간: From treatment initiation until disease progression or start of new anti-lymphoma therapy, assessed up to approximately 2 years
|
ORR is defined as the proportion of participants achieving a best overall response of complete response (CR) or partial response (PR), assessed by the investigator according to the Lugano 2014 response criteria for malignant lymphoma.
|
From treatment initiation until disease progression or start of new anti-lymphoma therapy, assessed up to approximately 2 years
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Disease Control Rate (DCR)
기간: From treatment initiation until disease progression, assessed up to approximately 2 years
|
DCR is defined as the proportion of participants achieving complete response (CR), partial response (PR), or stable disease (SD) per Lugano 2014 criteria.
|
From treatment initiation until disease progression, assessed up to approximately 2 years
|
|
Duration of Response (DOR)
기간: From first response until disease progression or death, assessed up to approximately 2 years
|
DOR is defined as the time from the first documented CR or PR to the first documented disease progression or death from any cause, whichever occurs first, among responders.
|
From first response until disease progression or death, assessed up to approximately 2 years
|
|
Time to Next Treatment (TTNT)
기간: From treatment initiation until start of next therapy or death, assessed up to approximately 2 years
|
TTNT is defined as the time from treatment initiation to the start of the next line of anti-lymphoma therapy or death from any cause, whichever occurs first.
|
From treatment initiation until start of next therapy or death, assessed up to approximately 2 years
|
|
Progression-Free Survival (PFS)
기간: From treatment initiation until disease progression or death, assessed up to approximately 2 years
|
PFS is defined as the time from treatment initiation to the first documented disease progression per Lugano 2014 criteria or death from any cause, whichever occurs first.
|
From treatment initiation until disease progression or death, assessed up to approximately 2 years
|
|
Overall Survival (OS)
기간: From treatment initiation until death from any cause, assessed up to approximately 2 years
|
OS is defined as the time from treatment initiation to death from any cause.
|
From treatment initiation until death from any cause, assessed up to approximately 2 years
|
|
Incidence of Adverse Events (Safety)
기간: From treatment initiation until 90 days after last dose, assessed up to approximately 2 years
|
Safety is assessed by the incidence, severity, and type of adverse events (AEs) and serious adverse events (SAEs), including adverse events of special interest such as cytokine release syndrome (CRS), graded per NCI CTCAE and, for CRS, per ASTCT consensus criteria.
|
From treatment initiation until 90 days after last dose, assessed up to approximately 2 years
|
|
Complete Response Rate (CRR)
기간: From treatment initiation until disease progression or start of new therapy, assessed up to approximately 2 years
|
CRR is defined as the proportion of participants achieving a best overall response of complete response (CR) per Lugano 2014 criteria.
|
From treatment initiation until disease progression or start of new therapy, assessed up to approximately 2 years
|
공동 작업자 및 조사자
스폰서
수사관
- 수석 연구원: Yanyan Liu, Henan Cancer Hospital
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- HNSZLYYNHL12
- 2026-254 (기타 식별자: Henan Cancer Hospital Medical Ethics Committee)
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .